Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

From the original abstract

Authors’ conclusion — excerpt

“The results of our meta-analysis revealed that retatrutide treatment decreases blood pressure and improves lipid profile by reducing total cholesterol, LDL-C, and triglyceride levels.”

From the abstract’s conclusions section. This is a short quotation from the authors, not a full study appraisal.

Read the full abstract & conclusion

How to read this paper

This paper brings together existing research. Its conclusions depend on the included studies and their methods; it is not a separate treatment trial.

A brief excerpt cannot capture the complete methods, results, adverse events, or limitations. Check the full abstract and original paper before interpreting the finding.

Publication & source

Why this paper is included: The compound is a named subject of the publication title.
Publication indexing: Journal Article · Meta-Analysis · Systematic Review
Indexed subjects: Humans · Antihypertensive Agents · Biomarkers · Blood Pressure · Dyslipidemias · Glucagon-Like Peptide-1 Receptor Agonists · Hypertension · Hypolipidemic Agents · Incretins · Lipids · Randomized Controlled Trials as Topic · Receptors, Gastrointestinal Hormone · Treatment Outcome · Glucagon-Like Peptide-1 Receptor · Fatty Acids · Peptides
Source checked: October 4, 2026. Years follow journal issues; online-first dates may differ.

Open PubMed record PMID 42371360 · Journal and full-text links

Educational research information. A publication does not verify the identity, quality, or safety of products sold here.

Back to Retatrutide studies